Securities Code: 000950
Securities Abbreviation: Chongqing Pharmaceutical Holdings
Announcement Number: 2026-012
Chongqing Pharmaceutical Holdings Co., Ltd. announces the proposed registration of debt financing products by its controlling subsidiary, Chongqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Chongqing Pharmaceutical"). This initiative aims to further broaden financing channels and optimize the financing structure. The categories of financing products include medium-term notes and ultra-short-term financing bonds for the year 2026. The specific details are as follows:
I. Previous Business Developments
(1) Medium-term Notes
On March 27, 2023, the first extraordinary general meeting of shareholders of Chongqing Pharmaceutical Holdings Co., Ltd. approved the proposal regarding the issuance of debt financing products by its controlling subsidiary, Chongqing Pharmaceutical Group Co., Ltd., agreeing to a proposed issuance scale of no more than RMB 1.5 billion. This matter was registered on September 5, 2023, with a registered amount of RMB 1.5 billion, valid for two years, with an actual financing balance of RMB 1.5 billion as of December 31, 2025. On March 25, 2024, the first extraordinary general meeting of shareholders of Chongqing Pharmaceutical Holdings Co., Ltd. approved the proposal regarding the issuance of debt financing products by its controlling subsidiary, agreeing to a proposed issuance scale of no more than RMB 2 billion. This matter was registered on August 5, 2024, with a registered amount of RMB 2 billion, valid for two years, with an actual financing balance of RMB 500 million as of December 31, 2025.